BMRN vs SER · P/E 40, rev $2.85B vs rev $56.0K
Biomarin Pharmaceutical Inc (BMRN) versus Serina Therapeutics Inc (SER) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Serina Therapeutics Inc (SER) is a biotechnology company listed on AMEX.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported SER revenue for 2024-12-31 was $56.0K. Net income was -$11.2M. Revenue was down 98.2% from 2023-12-31 to 2024-12-31. SER currently screens at market cap $29.7M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. SER currently screens at market cap $29.7M.
Not investment advice. Open the BMRN and SER stock pages for the full models.
Not investment advice.